Help

BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Employee Benefits

Cigna rejects costly ALS medication from coverage

February 09, 2023 Reprints

Cigna Corp. has changed its policy for a new and in-demand medicine for ALS, or amyotrophic lateral sclerosis, deciding not to cover it due to “a lack of clinical efficacy data,” Healthcare Dive reports. The drug Relyvrio, which Cigna called “experimental, investigational or unproven,” was developed by the Massachusetts-based biotechnology company Amylyx Pharmaceuticals and costs $158,000 per year.

1. Ozempic side-effect litigation may surge
2. DeSantis pledges to overhaul ACA with new health plan
3. Weight-loss drugs drives health insurance fund $15M deficit
4. Some BCBS plans start offering direct health care delivery
5. Cigna and Humana in advanced merger talks
6. Cigna plans to sell Medicare Advantage business for Humana merger approval

Help

Cigna rejects costly ALS medication from coverage

Readers Poll

Most Read in Employee Benefits

Sign up now for free access to this article and much more.

If you are already registered with Business Insurance, click here to Login

Please tell us a bit more about yourself in order to continue

About

Advertise

Reprints and Licensing

Resources